RECRUITINGPhase 2INTERVENTIONAL
Treating Postictal Symptoms Using Ibuprofen and Nifedipine
An Initial Clinical Study to Treat Postictal Symptoms
About This Trial
This study will evaluate the effect of ibuprofen or nifedipine on post-seizure hypoperfusion and neurological deficits in patients with epilepsy. One group will receive ibuprofen, another will receive nifedipine, and anther placebo.
Who May Be Eligible (Plain English)
Who May Qualify:
- age \> 16 yrs, frequent seizures (\>1 per week) and cognitive ability sufficient to complete neuropsychological testing.
Who Should NOT Join This Trial:
- multiple seizure onset zones, contraindications to CT or MR imaging, any contraindication to ibuprofen or nifedipine, as well as current or recent (\< 2 months) exposure COX-2 inhibitor or calcium channel blocker.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* age \> 16 yrs, frequent seizures (\>1 per week) and cognitive ability sufficient to complete neuropsychological testing.
Exclusion Criteria:
* multiple seizure onset zones, contraindications to CT or MR imaging, any contraindication to ibuprofen or nifedipine, as well as current or recent (\< 2 months) exposure COX-2 inhibitor or calcium channel blocker.
Treatments Being Tested
DRUG
Ibuprofen
Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
DRUG
Nifedipine
Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
DRUG
Placebo
Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
Locations (2)
Foothills Medical Centre
Calgary, Alberta, Canada
South Health Campus
Calgary, Alberta, Canada